Ritonavir-boosted paritaprevir, ombitasvir plus ribavirin could improve eGFR in patients with renal impairment and HCV: an Egyptian cohort.

Journal: Expert review of gastroenterology & hepatology
PMID: 30791838

Abstract

BACKGROUND: The present study aimed at evaluation of changes in estimated glomerular filtration rate (eGFR) among chronic Hepatitis C virus (HCV) patients with chronic kidney disease (CKD) Stages 3-5 who were treated with 12 weeks of ritonavir-boosted paritaprevir, ombitasvir plus ribavirin.

Authors

  • Mohamed Said
    a Endemic Medicine and Hepato-gastroenterology Department, Faculty of Medicine , Cairo University , Cairo , Egypt.
  • Heba Omar
    a Endemic Medicine and Hepato-gastroenterology Department, Faculty of Medicine , Cairo University , Cairo , Egypt.
  • Zeinab Soliman
    a Endemic Medicine and Hepato-gastroenterology Department, Faculty of Medicine , Cairo University , Cairo , Egypt.
  • Yasmin Saad
    a Endemic Medicine and Hepato-gastroenterology Department, Faculty of Medicine , Cairo University , Cairo , Egypt.
  • Hosam Dabes
    b Internal Medicine Department , Damanhour Medical National Institute , Damanhour , Egypt.
  • Sozan Hamed
    b Internal Medicine Department , Damanhour Medical National Institute , Damanhour , Egypt.
  • Kadri ElSaeed
    c Internal Medicine Department, Faculty of Medicine , Ain Shams University , Cairo , Egypt.
  • Yehia ElShazly
    c Internal Medicine Department, Faculty of Medicine , Ain Shams University , Cairo , Egypt.
  • Magdi ElSerafy
    a Endemic Medicine and Hepato-gastroenterology Department, Faculty of Medicine , Cairo University , Cairo , Egypt.

Keywords

External Resources

Popular Topics
Recent Journals